Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants

Design of the multi-center study is based on Phase 2a clinical data, which showed a decrease in the occurrence of severe bronchopulmonary dysplasia (BPD), a condition for which there are

Related Keywords

Japan ,Diego Ardig ,Hill Bio ,Development Head At Chiesi Group ,Chiesi Group ,National Institute Of Child Health ,Human Development ,Oak Hill ,Victoria Niklas ,Chief Medical Officer ,Oak Hill Bio ,Development Head ,National Institute ,Child Health ,